NXY-059 for the treatment of acute ischemic stroke.
By A. Shuaib, K. Lees, P. Lyden, J. Grotta, A. Dávalos, S. Davis, H. Diener, T. Ashwood, W. Wasiewski, U. Emeribe. New England Journal of Medicine, 2007
717 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/d53efbe5313c208a3748c8e50d20d2e03124d58f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
In Neurology
Citations in the corpus
- Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease (2019, background): “Also, the synthetic antioxidant NXY-059 failed to prove benefits in stroke patients upon costly development and clinical studies [122].”
- Neuroprotection for ischemic stroke: past, present and future. (2008, methodology): “The first trial, SAINT I, involved 1,722 patients (Lees et al., 2006); SAINT II enrolled 3,306 subjects (Shuaib et al., 2007).”
- A new penumbra: transitioning from injury into repair after stroke (2008, background): “However, the larger SAINT-2 trial did not replicate these initial finding”
- Can Animal Models of Disease Reliably Inform Human Studies? (2010, neutral): “infarction [4–7].”
- Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies (2021, background): “…clinical trials and meta-analyses have been conducted to evaluate the beneficial effects of antioxidants such as vitamin C, vitamin E, xanthine oxidase inhibitors, a-lipoic acid, and the synthetic agent NXY-059 (Khaw et al., 2001; Ziegler et al., 2004; Shuaib et al., 2007; Bredemeier et al., 2018).”